# MoonLake Immunotherapeutics (MLTX): Dividend & Fundamentals

> Markdown mirror of https://www.dividenddata.com/stocks/mltx for AI agents. Same live data as the HTML page, regenerated on the same refresh cycle. Not investment advice.

- Sector: Healthcare · Industry: Biotechnology
- Exchange: NASDAQ · Trading currency: USD

MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Im...

## Quote & Key Metrics

As of 2026-10-23:

| Metric | Value |
|---|---|
| Price | $11.85 USD |
| Market Cap | $1.01B |
| P/E (TTM) | — |
| EPS (TTM) | −$3.84 |
| 52-Week Range | $9.37 – $23.29 |
| Dividend Yield (TTM) | — |

## Dividend

MLTX has no dividend payment history in our records.

## Frequently Asked Questions

### What does MoonLake Immunotherapeutics do?

MoonLake Immunotherapeutics (MLTX) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

### What is MLTX's market cap?

MoonLake Immunotherapeutics (MLTX) has a market capitalization of approximately $1.01 billion, as of October 23, 2026, based on the most recent share price and shares outstanding.

### Does MLTX pay a dividend?

No, MoonLake Immunotherapeutics (MLTX) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

### Is MLTX profitable?

MoonLake Immunotherapeutics (MLTX) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

### Has MLTX ever paid a dividend?

No. Dividend Data's records show no dividend payments from MoonLake Immunotherapeutics (MLTX). A first dividend would appear on the Dividend tab once it is declared.

## More on Dividend Data

- Overview (HTML): https://www.dividenddata.com/stocks/mltx
- Dividend history & safety: https://www.dividenddata.com/stocks/mltx/dividend
- Earnings & EPS: https://www.dividenddata.com/stocks/mltx/earnings
- Financial statements: https://www.dividenddata.com/stocks/mltx/financials/income
- Valuation multiples: https://www.dividenddata.com/stocks/mltx/valuation
- Peer comparison: https://www.dividenddata.com/stocks/mltx/peers

Data sourced from primary filings and market data providers; see https://www.dividenddata.com/methodology.